Illumina Introduces Its Most Powerful and Sustainable Sequencer Yet at Medlab Middle East 2023

The NovaSeq X Plus system is the most powerful and most sustainable sequencer from Illumina and enables laboratories to complete their most ambitious ultra-high-throughput projects. Labs can scale their studies with three flow cell types and up to 16 Tb output per run on the dual flow cell NovaSeq X Plus system or up to 8 Tb on the single flow cell NovaSeq X system. Ultra-high-density flow cells and ultra-high-resolution optics enable output of up to 26 billion single reads per flow cell. XLEAP-SBS chemistry delivers the highest level of data accuracy and performance, and the increased stability enables remarkable sustainability benefits. The DRAGEN Bio-IT Platform, available onboard or in the cloud, provides award-winning accuracy for rapid, easy-to-use, and efficient genomic data analysis.

At Medlab Middle East 2023, Illumina is also demonstrating the NextSeq 1000 and NextSeq 2000 sequencing platforms that are redesigned from the ground up. Their flexibility, affordability, and scalability help both new and experienced users achieve fast turnaround times and reduced operating costs. With the wide range of available flow cells, they support a variety of applications including single-cell gene expression, special transcriptomics, whole-exome sequencing, total RNA sequencing, shotgun metagenomics and infectious disease testing.

Additionally, Illumina is holding a half-day workshop on Genomics for Rare Diseases in the Middle East, featuring the latest findings related to the genomic basis of rare diseases and providing powerful insights into disease mechanisms and therapeutic approaches. As genomic sequencing becomes more available in the hospital setting, the expert panel discussion will be examining standardization, drivers & local challenges to implementation of genomic sequencing and how this is changing clinical practice. The program consists of scientific presentations from top experts in rare diseases, diagnostics and targeted testing followed by Q&A sessions. Guest speakers will be joining panel discussion with Illumina experts to identify the research, regulatory and access policy drivers to enable integration of whole genome sequencing into a healthcare setting.

Related Links:
Illumina Inc.